Restructuring the Group Production Framework and Strengthening Coordination
First written in FY2016. 13 of 17 entries say "Advanced", first in FY2020. Latest entry: 2026-09-30.
1 other company's latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「On 10 January 2025, the Company entered into a merger agreement under which the Company would be the surviving company and its wholly owned subsidiary, Daiwa Yakuhin Kogyo Co., Ltd., would be the absorbed company. The merger was carried out effective 1 June 2025.」
The absorption-type merger with Daiwa Yakuhin Kogyo Co., Ltd. was carried out effective 1 June 2025, completing the integration of the Group's production system from the planning stage. - FY2025AdvancedAnnual report
「Daiwa Yakuhin Kogyo Co., Ltd. manufactures APIs for prescription pharmaceuticals in Toyama, as does the Company, serving both the Company and external customers. Through the absorption-type merger, the Company aims to eliminate the separation between the 2 organizations, enabling it to carry out its strength, integrated production from APIs through finished dosage forms, with higher quality and efficiency, and to fulfill its responsibility for stable supply more reliably.」
Daiwa Yakuhin Kogyo Co., Ltd. was absorbed through a merger effective 1 June 2025, concretely implementing organizational integration to improve the efficiency of integrated production from APIs through finished dosage forms and stable supply. - FY2025-H1AdvancedAnnual report
「During the current interim consolidated accounting period, the company made additional investments in 千輝薬業（安徽）有限責任公司 and 安徽鼎旺医薬有限公司. As a result, the companies became associates and were included within the scope of application of the equity method.」
The Company made additional investments in 2 production and sales partners in China, strengthening the relationships through capital ties and application of the equity method. - FY2024AdvancedAnnual report
「Role allocation and optimization across 4 API production sites」
Regarding optimization of the production system, including operations in Japan and China, the Company specifies the allocation of roles and optimization across 4 API production sites as a concrete measure in its new medium-term management plan. - FY2024-Q1AdvancedAnnual report
「API sales for generic pharmaceuticals, including APIs for anti-inflammatory analgesics and antiplatelet agents, remained solid, supported in part by increased production at the Seventh API Building, which began commercial production in January 2023. Net sales were ¥5,670 million, up 25.0% year on year.」
The Company states that increased production at the Seventh API Building, which began commercial production in January 2023, contributed to higher API sales. - FY2023AdvancedAnnual report
「As part of efforts to optimize the production system involving the Company, its subsidiary Daiwa Yakuhin Kogyo Co., Ltd., and its equity-method investees Qianhui Pharmaceutical (Anhui) Co., Ltd. and Anhui Dingwang Pharmaceutical Co., Ltd., and to expand production capacity, the Company constructed a new API facility equipped with automated production equipment, the Seventh API Building, on the site of its head-office plant. It was completed in May 2022 and began operations in January 2023.」
The Company reports specific progress on the Seventh API Building equipped with automated production equipment, which began operations in January 2023 following its completion in May 2022. - FY2022AdvancedAnnual report
「As part of efforts to optimize the production system involving the Company, its subsidiary Daiwa Yakuhin Kogyo Co., Ltd., and its equity-method investees Qianhui Pharmaceutical (Anhui) Co., Ltd. and Anhui Dingwang Pharmaceutical Co., Ltd., and to expand production capacity, the Company constructed a new API facility equipped with automated production equipment, the Seventh API Building, on the site of its head-office plant. The facility was completed in May 2022, further strengthening the stable supply system and safety measures for pharmaceutical APIs.」
The Seventh API Building, equipped with automated production equipment and planned as part of the production system optimization measures in Japan and China, was completed in May 2022. - FY2022-Q1AdvancedAnnual report
「On 29 September 2021, the Company issued its Second Series of Stock Acquisition Rights with a provision for revision of the exercise price through a third-party allotment. The specific uses of the funds to be raised are: ① construction of the Seventh API Building and installation of manufacturing equipment at the head-office plant (¥1,502,000,000); ② construction of the new Research Building, the Comprehensive Research Center, at the head office (¥2,600,000,000); and ③ expansion of packaging and manufacturing equipment at the head-office plant (¥652,851,000).」
In connection with optimizing the API production system across Japan and China, the Company specifies the construction of the previously planned Seventh API Building and the installation of manufacturing equipment as specific uses of funds raised through stock acquisition rights. - FY2020AdvancedAnnual report
「As part of efforts to optimize the production system involving the Company, its subsidiary Daiwa Yakuhin Kogyo Co., Ltd., and its equity-method investees Qianhui Pharmaceutical (Anhui) Co., Ltd. and Anhui Dingwang Pharmaceutical Co., Ltd., and to expand production capacity, the Company plans to construct a new API facility equipped with automated production equipment, the Seventh API Building, on the site of its head-office plant. The facility is intended to further strengthen the stable supply system and safety measures for pharmaceutical APIs. Construction is scheduled to begin in November 2020, with completion scheduled for December 2021.」
The Company specifies the targets of its API production system optimization and provides details of the plan to construct the Seventh API Building, equipped with automated production equipment, including the scheduled start and completion dates. - FY2019Adding a target to the API production systemAnnual report
「The company recognizes the following as important issues, including optimizing the production system for the API business involving itself, its subsidiary 大和薬品工業株式会社, and its investees 千輝薬業(安徽)有限責任公司 and 安徽鼎旺医薬有限責任公司, and strengthening coordination in the drug product business between itself and its subsidiary 大桐製薬(中国)有限責任公司.」
Anhui Dingwang Pharmaceutical Co., Ltd. is specifically identified, in addition to the existing business partners, as a target for optimization of the active pharmaceutical ingredient (API) production system. - FY2018RestatedAnnual report
「For the API business, the company plans to optimize the production system involving itself, its subsidiary 大和薬品工業株式会社, and its investee 千輝薬業(安徽)有限責任公司. For the drug product business, it plans to strengthen coordination between itself and its subsidiary 大桐製薬（中国）有限責任公司.」
The company continues to identify optimization of the API production system and stronger coordination with the Chinese subsidiary for drug products as issues. - FY2017ReframedAnnual report
「For the API business, the company plans to optimize the production system involving itself, its subsidiary 大和薬品工業株式会社, and its investee 千輝薬業(安徽)有限責任公司. For the drug product business, it plans to strengthen coordination between itself and its subsidiary 大桐製薬(中国)有限責任公司.」
The wording for APIs has been revised from “restructuring” to “optimization,” while stronger coordination with the Chinese subsidiary continues for drug products. - FY2016First statedAnnual report
「For the API business, the company plans to restructure the production system involving itself, its subsidiary 大和薬品工業株式会社, and its investee 千輝薬業(安徽)有限責任公司. For the drug product business, it plans to strengthen coordination between itself and its subsidiary 大桐製薬(中国)有限責任公司.」
For APIs, the company identifies the restructuring of production across multiple sites as an issue, while for drug products it identifies stronger coordination with the Chinese subsidiary.